Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 10Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 5Head and Neck Neoplasms 4Carcinoma, Renal Cell 4Turcot syndrome 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hodgkin Disease 2Glioblastoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Biliary Tract Neoplasms 2Advanced Endometrial Cancer 2Tongue Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Thyroid Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous NSCLC 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1

Interventions

pembrolizumab 1Vinorelbine 1Pemetrexed 1Paclitaxel 1Nivolumab 1Gemcitabine 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lung Diseases, Interstitial × pembrolizumab × Clear all
NCT07420439 2026-04-27

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Intergroupe Francophone de Cancerologie Thoracique

Phase 2 Not yet recruiting
108 enrolled

Lung Diseases, Interstitial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡